Biologics & Biosimilars

FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

November 20, 2019 • By Michele B. Kaufman, PharmD, BCGP

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

October 14, 2019 • By Mary Choy, PharmD, BCGP, FASHP

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

September 16, 2019 • By Michele B. Kaufman, PharmD, BCGP

Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel

August 12, 2019 • By Deena Beasley

Samsung Bioepis Humira Biosimilar Wins FDA Approval

July 30, 2019 • By Aakash Jagadeesh Babu and Bernard Orr

Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients

July 22, 2019 • By Michele B. Kaufman, PharmD, BCGP

Ixekizumab vs. Adalimumab for PsA: How Do They Compare?

July 1, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

May 29, 2019 • By Michele B. Kaufman, PharmD, BCGP

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

May 29, 2019 • By Allison Martell & Allison Lampert

Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

May 21, 2019 • By Michele B. Kaufman, PharmD, BCGP

1
2
3
…
30
Next Page »